5-amino-1mq clinical trial human Peptide Therapy 5-Amino-1MQ Peptide Dosing Guide: Oral – 5-Amino-1MQ Human Clinical Trials: 2026

Doses up to 60mg/kg per day produced no observable toxicity

Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies

The OPTIONS study was described as a double-blind, placebo-controlled trial in 502 adults with obesity who received oral AOD9604 or placebo once daily for 24 weeks together with a diet-and-exercise program

in diet-induced obese mice, 5-Amino-1-MQ significantly reduces total body weight, fat mass, and adipocyte size, while improving insulin sensitivity and glucose tolerance 2,3

Potential Benefits of AOD-9604 AOD-9604 has gained attention for its fat-burning properties, but its potential benefits extend beyond simple weight loss

This is why we view it as one component of a larger, personalized health strategy designed for lasting performance, not just a temporary fix